SITE011-0261

withdrawn

Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer Phase III · Site: SITE011 (ITA) (Dr. Jansen) · consented 2022-12-29

Adverse events

Serious AEs

Open data queries

Luna dropout signal

–

Adverse events

moderate assessed 2026-08-18

Grade 2 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2023-06-26 (study day 166); relationship: N

moderate assessed 2026-08-18

Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2024-01-02 (study day 356); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Fatigue — outcome: RECOVERED/RESOLVED; onset 2024-01-11 (study day 365); relationship: not assessed

severe serious assessed 2026-08-18

Grade 4 Nausea — outcome: RECOVERED/RESOLVED; onset 2024-02-24 (study day 409); relationship: not assessed; serious criteria: life-threatening

mild assessed 2026-08-18

Grade 1 Neutropenia — outcome: UNKNOWN; onset 2024-03-07 (study day 421); relationship: N

mild assessed 2026-08-18

Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2024-08-28 (study day 595); relationship: Y

mild assessed 2026-08-18

Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2024-11-20 (study day 679); relationship: N

Data queries

No data queries.

☾ Luna engagement

This participant doesn't use Luna.